Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock
- Conditions
- Severe SepsisSeptic Shock
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Kompetenznetz Sepsis
- Target Recruit Count
- 600
- Registration Number
- NCT00534287
- Locations
- 🇩🇪
Klinikum Oldenburg - Dep. of Anesthesiology, Intensive Care Medicine, Emergency Medicine, Pain Therapy, Oldenburg, Germany
🇩🇪University Hospital Ulm - Dep. of Internal Medicine II, Ulm, Germany
🇩🇪University Hospital Münster - Dep. of Anesthesiology and Intensive Care Medicine, Münster, Germany
Study Evaluating the Effect of Lecozotan SR on the QTc Interval
- Conditions
- Alzheimer DiseaseHealthy
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00499642
BAY12-8039: 5 Days for Sinusitis vs Placebo
- Conditions
- Sinusitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 374
- Registration Number
- NCT00492024
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
- Conditions
- Infection
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 804
- Registration Number
- NCT00492726
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
- Conditions
- SinusitisBacterial Infections
- Interventions
- Drug: Amoxicillin/Clavulanate
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 293
- Registration Number
- NCT00493038
Phase 1 Thorough QT Study in Young Healthy Volunteers
- Conditions
- Postoperative Pain
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00485667
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
- Conditions
- Bronchitis, ChronicLung Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1404
- Registration Number
- NCT00473460
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application
- Conditions
- Conjunctical Flora
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Stanford University
- Registration Number
- NCT00466570
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
- Conditions
- Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2011-09-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 171
- Registration Number
- NCT00464438
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
- Conditions
- Mycobacterium Tuberculosis
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 15
- Registration Number
- NCT00460759
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.